|
MechanismTubulin inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date29 Dec 1992 |
Phase IIa Trial Evaluating the Safety and Therapeutic Effect of SMS001 as an Adjuvant Therapy to Control Tumor Recurrence in Stage Ib-IIIa (N2) Non-Small Cell Lung Cancer (NSCLC) Patients
This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating lung cancer patients.
100 Clinical Results associated with ToLymph Inc.
0 Patents (Medical) associated with ToLymph Inc.
100 Deals associated with ToLymph Inc.
100 Translational Medicine associated with ToLymph Inc.